Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | BCHE | P06276 | 5/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119791 | 1.00 | KDM4E (0.48) | KDM4EKMT2ABACE1AXLGFER | |
| SCHEMBL18585748 | 0.98 | KDM4E (0.47) | KDM4EKMT2ABACE1AXLGFER | |
| SCHEMBL118875 | 0.86 | KDM4E (0.57) | KDM4EKMT2ABACE1AXLGFER | |
| SCHEMBL31399981 | 0.86 | KDM4E (0.57) | KDM4EKMT2ABACE1AXLGFER | |
| SCHEMBL11725621 | 0.86 | KDM4E (0.57) | KDM4EKMT2ABACE1AXLGFER | |
| SCHEMBL1138685 | 0.80 | PIK3CG (0.55) | KDM4EKMT2ABACE1NQO1MAPT | |
| SCHEMBL121409 | 0.79 | NQO1 (0.46) | KDM4ENQO1MAPTALDH1A1GAA | |
| SCHEMBL13731131 | 0.77 | KMT2A (0.52) | KDM4EKMT2ABACE1AXLGFER | |
| SCHEMBL2178248 | 0.77 | KDM4E (0.48) | KDM4EKMT2AMAPTNPC1TP53 | |
| SCHEMBL428426 | 0.77 | KDM4E (0.48) | KDM4EKMT2AMAPTNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2020-07-23 | — | — | US | claimed |
| US-20180290985-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2018-10-11 | — | — | US | claimed |
| EP-3344250-A2 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | Rexahn Pharmaceuticals, Inc. (US) | 2018-07-11 | — | — | EP | claimed |
| US-20170066726-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | claimed |
| WO-2017040980-A2 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | WO | claimed |
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-10570101-B2 | Quinoxalinyl-piperazinamide methods of use | REXAHN PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570101-B2 | Quinoxalinyl-piperazinamide methods of use | REXAHN PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180290985-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| EP-3344250-A2 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | Rexahn Pharmaceuticals, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9969698-B2 | Quinoxalinyl-piperazinamide methods of use | REXAHN PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170066726-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066726-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066726-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | REXAHN PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-8598173-B2 | 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-12-03 | — | — | US | disclosed |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-8314100-B2 | 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-1819698-B1 | 1-[(6-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | HRAS, CDK4, KRAS | KDM4E 502/4885KMT2A 549/4885BACE1 4848/4885 |
| US-10570101-B2 | Quinoxalinyl-piperazinamide methods of use | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885KMT2A 2050/4885BACE1 2566/4885 |
| US-20180290985-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885KMT2A 2050/4885BACE1 2566/4885 |
| US-20200231553-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885KMT2A 2050/4885BACE1 2566/4885 |
| US-20170066726-A1 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | NQO2, CYP3A5, NQO1 | KDM4E 3492/4885KMT2A 2050/4885BACE1 2566/4885 |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | HRAS, CDK4, KRAS | KDM4E 843/4885KMT2A 814/4885BACE1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.